Skip to main content
KBIO COMPANY Inc. logo

KBIO COMPANY Inc. — Investor Relations & Filings

Ticker · 038530 ISIN · KR7038530002 KO Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 038530

About KBIO COMPANY Inc.

https://kbio.com/

KBio specializes in plant-based manufacturing of biologics. The company utilizes its proprietary RP3 platform, which leverages plants as biofoundries for the efficient and sustainable production of high-quality proteins, therapeutics, and other bioactive compounds. This innovative approach is designed to surpass traditional manufacturing limitations, enabling the rapid development and large-scale production of biomolecules. The company's focus includes developing novel product candidates such as antibody therapies to address public health challenges and areas of high unmet medical need.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is explicitly titled '분기보고서' (Quarterly Report) for the period 2026.01.01–2026.03.31 (1st quarter), contains comprehensive financial tables, business descriptions, sales data, asset information, and other substantive interim reporting disclosures typical of a statutory quarterly filing. Q1 2026
2026-05-15 Korean
[기재정정]분기보고서 (2026.03)
Interim / Quarterly Report Classification · 96% confidence The document is clearly titled “분기보고서” (Korean for Quarterly Report) for the period January 1, 2026 to March 31, 2026, and includes detailed financial statements, notes (including related party transactions), company overview, business activities, and footnotes. It is a comprehensive interim report — not merely an announcement or certification — and exceeds 5,000 characters. Therefore it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
주권매매거래정지해제 (액면병합 주권 변경상장)
Regulatory Filings Classification · 95% confidence The document is a regulatory notice regarding the lifting of a trading suspension for the common shares of K-BioLabs, citing market rules and effective date. It does not present financial data, call transcripts, management changes, or delisting; rather it is a general regulatory announcement. Therefore it best fits the Regulatory Filings category (RNS).
2026-05-11 Korean
유형자산취득결정(종속회사의주요경영사항)
Regulatory Filings
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 92% confidence The document is an official regulatory disclosure titled “임원ㆍ주요주주 특정증권등 소유상황보고서” (“Report on Ownership Status of Specific Securities by Officers & Major Shareholders”) filed with the Securities & Futures Commission and the Korea Exchange. It details changes in shareholding levels (initial, current, change) of a major shareholder (exceeding 10%) and an officer. This corresponds to notifications of changes in significant share ownership crossing thresholds, matching the Major Shareholding Notification (MRQ) category. It is not an annual or interim report, earnings release, board change, dividend notice, or other category.
2026-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean regulatory filing titled “임원ㆍ주요주주 특정증권등 소유상황보고서” which discloses a company officer’s and major shareholder’s specific securities ownership and changes (including share counts, ratios, increases/decreases). This matches the definition of Director’s Dealing (insider share transactions and holdings). It is not a general report announcement nor an annual/interim report. Therefore, the correct classification is DIRS.
2026-04-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.